2006
DOI: 10.1586/14737175.6.10.1413
|View full text |Cite
|
Sign up to set email alerts
|

Eletriptan: a review and new perspectives

Abstract: Eletriptan is a second-generation 5-hydroxytryptamine(1B/1D) receptor agonist, or triptan, indicated for the acute treatment of migraine. Eletriptan has a favorable pharmacokinetic and pharmacodynamic profile expressed by bioavailability, half-life and high selectivity for cranial arteries. It has been shown to be effective and well tolerated in a wide preapproval development program, which included over 11,000 patients and treated more than 74,000 migraine attacks. In clinical trials, eletriptan has been demo… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
1
0
1

Year Published

2008
2008
2021
2021

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(2 citation statements)
references
References 54 publications
0
1
0
1
Order By: Relevance
“…Ez a leglipofilebb triptán, jól tolerálható. Főleg a CYP3A4 izoenzim által metabolizálódik, N-demetil-eletriptan aktív metabolit keletkezik, gyakoribbak a KIR-i mellékhatások [66][67].…”
Section: Orvostudományi éRtesítőunclassified
“…Ez a leglipofilebb triptán, jól tolerálható. Főleg a CYP3A4 izoenzim által metabolizálódik, N-demetil-eletriptan aktív metabolit keletkezik, gyakoribbak a KIR-i mellékhatások [66][67].…”
Section: Orvostudományi éRtesítőunclassified
“…Eletriptan is a second-generation 5-HT 1B/1D receptor agonist indicated for the acute treatment of migraine (118). A case of serotonin syndrome and rhabdomyolysis induced by concomitant use of eletriptan, fluoxetine, and SJW has been reported in a 28-year-old woman (119).…”
Section: Antimigraine Drugsmentioning
confidence: 99%